<DOC>
	<DOCNO>NCT02262728</DOCNO>
	<brief_summary>The purpose study assess efficacy 12-week regimen contain simeprevir , daclatasvir sofosbuvir participant decompensated liver disease ( liver function insufficient ) due genotype 1 4 Hepatitis ( inflammation liver ) C virus ( HCV ) infection assess sustain virologic response 12-weeks end study drug treatment ( SVR12 ) .</brief_summary>
	<brief_title>An Efficacy , Safety Pharmacokinetics Study Simeprevir , Daclatasvir Sofosbuvir Participants With Chronic Hepatitis C Virus Genotype 1 4 Infection Decompensated Liver Disease</brief_title>
	<detailed_description>This open-label ( people know treatment participant receive ) Phase 2 study investigate efficacy , safety pharmacokinetics simeprevir , daclatasvir sofosbuvir treatment-naive ( participant never receive HCV treatment approve investigational agent ) treatment - experience ( participant fail least one previous course [ Pegylated ] interferon [ ( Peg ) IFN ] , without Ribavirin ) participant . Participants assign 1 2 panel : Panel 1 ( n=20 ) : Child-Pugh score le ( &lt; ) 7 evidence portal hypertension ( confirm presence esophageal varix HVPG great equal [ &gt; = ] 10 mm Hg ) ; Panel 2 ( n=20 ) : Child-Pugh score 7 9 ( extreme include ) . The total study duration participant approximately 276 week . The study consist 3 part : Screening Phase ( approximately 4 week ) open-label treatment Phase ( Week 4 16 ) follow-up Phase ( 5 year actual end study drug treatment ) . Participants receive simeprevir ( 150 milligram [ mg ] capsule ) , daclatasvir ( 60 mg tablet ) sofosbuvir ( 400 mg tablet ) orally daily 12 week . Efficacy primarily evaluate percentage participant SVR12 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Documented chronic Hepatitis C virus ( HCV ) infection : diagnosis HCV ( &gt; ) 6 month Screening visit , either detectable HCV ribonucleic acid ( RNA ) , HCV positive antibody presence histological change consistent chronic hepatitis HCV genotype 1 4 infection HCV RNA plasma level &gt; 10,000 international unit per milliliter ( IU/mL ) ( determine screen ) Presence cirrhosis , define FibroScan result &gt; 14.5 kilopascals ( kPa ) Screening HCV treatmentnaive participant : participant receive treatment approve investigational drug treatment HCV infection HCV treatmentexperienced participant : participant least 1 documented previous course nondirectacting antiviral agent ( DAA ) , interferon ( IFN ) base HCV therapy ( without Ribavirin [ RBV ] ) . Last dose previous course occur least 2 month prior Screening Decompensated liver disease : Panel 1 : Child Pugh A ( mild hepatic impairment ) evidence portal hypertension [ confirm presence esophageal varix gastroscopy hepatic venous pressure gradient ( HVPG ) great equal ( &gt; = ) 10 millimeter mercury ( mm Hg ) ] , Panel 2 : ChildPugh B ( moderate hepatic impairment ) 7 9 ( extreme include ) Coinfection HCV genotype Coinfection human immunodeficiency virus ( HIV ) 1 2 ( positive HIV1 HIV2 antibodies test Screening ) Coinfection hepatitis B virus ( hepatitis B surface antigen [ HBsAg ] positive ) Any evidence liver disease nonHCV etiology . This include , limited , acute hepatitis A infection , drug alcoholrelated liver disease , autoimmune hepatitis , hemochromatosis , Wilson 's disease , alpha1 antitrypsin deficiency , nonalcoholic steatohepatitis , primary biliary cirrhosis , nonHCV liver disease consider clinically significant Investigator Use disallow therapy plan first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Daclatasvir</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Decompensated Liver Disease</keyword>
</DOC>